Tsunakawa Yuki, Hamada Michito, Matsunaga Yurina, Fuseya Sayaka, Jeon Hyojung, Wakimoto Yuji, Usui Toshiaki, Kanai Maho, Mizuno Seiya, Morito Naoki, Takahashi Satoru
Department of Anatomy and Embryology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan.
Ph.D. Program in Human Biology, School of Integrative and Global Majors, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki 305-8575, Japan.
Exp Anim. 2019 Feb 26;68(1):103-111. doi: 10.1538/expanim.18-0093. Epub 2018 Oct 26.
Multicentric carpotarsal osteolysis (MCTO) is a condition involving progressive osteolysis of the carpal and tarsal bones that is associated with glomerular sclerosis and renal failure (MCTO nephropathy). Previous work identified an autosomal dominant missense mutation in the transactivation domain of the transcription factor MAFB as the cause of MCTO. Several methods are currently used for MCTO nephropathy treatment, but these methods are invasive and lead to severe side effects, limiting their use. Therefore, the development of alternative treatments for MCTO nephropathy is required; however, the pathogenesis of MCTO in vivo is unclear without access to a mouse model. Here, we report the generation of an MCTO mouse model using the CRISPR/Cas9 system. These mice exhibit nephropathy symptoms that are similar to those observed in MCTO patients. Mafb mice show developmental defects in body weight from postnatal day 0, which persist as they age. They also exhibit high urine albumin creatinine levels from a young age, mimicking the nephropathic symptoms of MCTO patients. Characteristics of glomerular sclerosis reported in human patients are also observed, such as histological evidence of focal segmental glomerulosclerosis (FSGS), podocyte foot process microvillus transformation and podocyte foot process effacement. Therefore, this study contributes to the development of an alternative treatment for MCTO nephropathy by providing a viable mouse model.
多中心腕跗骨溶解症(MCTO)是一种涉及腕骨和跗骨进行性骨溶解的病症,与肾小球硬化和肾衰竭(MCTO肾病)相关。先前的研究确定转录因子MAFB反式激活结构域中的常染色体显性错义突变是MCTO的病因。目前有几种方法用于治疗MCTO肾病,但这些方法具有侵入性并会导致严重的副作用,限制了它们的应用。因此,需要开发针对MCTO肾病的替代治疗方法;然而,在没有小鼠模型的情况下,MCTO在体内的发病机制尚不清楚。在此我们报告利用CRISPR/Cas9系统构建了MCTO小鼠模型。这些小鼠表现出与MCTO患者中观察到症状相似的肾病症状。Mafb小鼠从出生后第0天起就表现出体重发育缺陷,且随着年龄增长持续存在。它们还在幼年时就表现出血清尿白蛋白肌酐水平升高,类似于MCTO患者的肾病症状。在人类患者中报道的肾小球硬化特征也能被观察到了,如局灶节段性肾小球硬化(FSGS)、足细胞足突微绒毛转化和足细胞足突消失的组织学证据。因此,本研究通过提供一个可行的小鼠模型,为MCTO肾病替代治疗方法的开发做出了贡献。